Table 2. Active clinical trials of proteasome inhibition in AML patients.
| Trial no. | Phase | Patientsa | Intervention |
|---|---|---|---|
| NCT01861314 | I | Poor-risk or r/r AML | Bortezomib Sorafenib Decitabine |
| NCT02312012 | I | Relapsed AML/MDS post allogeneic HSCT | Bortezomib Lenalidomide |
| NCT02352558 | I | Advanced or r/r hematologic malignancies (inc. AML) | Bortezomib Napabucasin (BBI608) |
| NCT01137747 | I | R/r AML and ALL | Carfilzomib |
| NCT01534260 | I/II | Complex, poor-risk, or FLT3-ITD+ AML | Bortezomib Vorinostat Sorafenib |
| NCT02419755 | II | MLLb rearranged r/r hematologic malignancies (inc. AML), age ⩽21 years | Bortezomib Vorinostat |
| NCT01736943 | II | R/r AML | Bortezomib Pegylated liposomal doxorubicin |
| NCT01420926 | II | New AML, age ≥60 years | Bortezomib Decitabine |
| NCT01371981 | III | New AML, age <30 years | Bortezomib Sorafenib |
a
R/r, relapsed/refractory.
b
MLL, mixed-lineage leukemia.